These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Kinetics of beta-chemokine levels during anti-HIV therapy.
    Author: Aleman S, Pehrson P, Sönnerborg A.
    Journal: Antivir Ther; 1999; 4(2):109-15. PubMed ID: 10682156.
    Abstract:
    Chemokines are pro-inflammatory cytokines that inhibit human immunodeficiency virus type 1 (HIV-1) replication in vitro. We studied the kinetics of the beta-chemokines, macrophage inhibitory protein (MIP)-1 alpha, MIP-1 beta, RANTES, and monocyte chemotactic protein (MCP)-1 in plasma during 12 months of antiretroviral therapy in 26 HIV-1-infected patients and in 11 untreated subjects. Eleven patients with moderate immunodeficiency had HIV-1 RNA levels < 50 copies/ml after 1 year, whereas 12 out of 15 patients with severe immunodeficiency had detectable virus. At baseline, MCP-1 levels correlated positively with HIV-1 RNA and DNA levels and inversely with CD4 cell counts. A reverse pattern was seen for the MIP-1 beta levels. No correlation was seen between MIP-1 alpha or RANTES and any of the parameters. Also, there was a dichotomy between the different beta-chemokines in response to therapy. Decreases of MCP-1 and RANTES levels were found, but no durable changes of MIP-1 alpha and MIP-1 beta. The MCP-1 levels rebounded back to baseline after 1 year in the patients who responded virologically, which could possibly reflect an increased immune activation. The biological consequences of the changes in beta-chemokines levels during antiretroviral treatment are still unknown and deserve further studies.
    [Abstract] [Full Text] [Related] [New Search]